Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

October 26-28, 2017

New York, New York
Sheraton New York

Scientific Agenda

In addition to the General Session at this year's Lymphoma & Myeloma, we are excited to offer a concurrent track specifically designed to meet the educational needs of nurses and advanced practitioners who treat hematologic malignancies.

 

GENERAL SESSION


Thursday, October 26, 2017

8:00 am

Welcome and introduction
Morton Coleman, MD

MYELOMA SESSION

8:05 am

Introduction to Myeloma Session
Ruben Niesvizky, MD

Session I: Precision Medicine in Myeloma

Moderator: Moderator invited

8:10 am

Sequencing the genome in myeloma: Pitfalls and opportunities in the clinic
Gareth J. Morgan, MD, PhD, FRCP, FRCPath

8:30 am

Harnessing the cell cycle: Applying the state of the art
Selina Chen-Kiang, PhD

8:50 am

How many myelomas are there? Do we treat them differently?
Nikhil C. Munshi, MD

9:10 am

DEBATE: MRD, Ready for Primetime?

Pro
C. Ola Landgren, MD, PhD

Con
Paul G. Richardson, MD

9:40 am

Break

Session II: Immuno Oncology in Myeloma

Moderator: Hearn Jay Cho, MD, PhD

10:00 am

Role of vaccine therapy in multiple myeloma
David E. Avigan, MD

10:20 am

Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?
Joseph R. Mikhael MD, MEd, FRCPC

10:40 am

The future in multiple myeloma: BiTE immunotherapy, CAR-T, and immune checkpoint inhibitors
Adam D. Cohen, MD

11:00 am

Panel discussion

Session III: Treatment I

Moderator: Ruben Niesvizky, MD

11:15 am

Precursor disorders and smoldering myeloma: Are they curable?
Adriana C. Rossi, MD

11:35 am

DEBATE: Which initial therapy for younger fit patients is best?

KRD and VRD
Ajai Chari, MD

CyBord and BiRd
Joseph R. Mikhael MD, MEd, FRCPC

12:05 pm

Panel discussion

12:20 pm

Luncheon

Session IV: Treatment II

Moderator: Adriana Rossi, MD

1:50 pm

DEBATE: One size fits all? Should everyone eligible get upfront autologous stem cell transplant?

Pro
Phillipe Moureau, MD

Con
James R. Berenson, MD

2:20 pm

DEBATE: In the relapsed patient, what would be the ideal treatment?

IMid plus protease inhibitor?
Speaker invited

IMid plus monoclonal antibody?
Tomer M. Mark, MD, MSc

2:50 pm

Panel discussion

Session V: Treatment III

Moderator: Cara Rosenbaum, MD

3:10 pm

Is there a role for allogeneic transplant in any young, fit myeloma patient?
Guenther Koehne, MD, PhD

3:30 pm

Targeting tumor protein 53 (p53): Is there anything we can do therapeutically?
Sagar Lonial, MD

3:50 pm

New horizons in the treatment of relapsed and refractory myeloma
Kenneth C. Anderson, MD

4:10 pm

Break

Session VI: Treatment IV

Moderators: Morton Coleman, MD and Ruben Niesvizky, MD

4:30 pm

The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation

Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Presenter: Phillipe Moureau, MD
Recipient: Thierry Facon, MD

4:40 pm

Keynote Lecture: Current Approach to the Treatment for the elderly myeloma patient
Thierry Facon, MD

Session VII: Treatment V - The Bone and Myeloma

Moderator: Roger N. Pearse, MD, PhD

5:10 pm

Basic science meets the bone
Suzanne Lentzsch, MD, PhD

5:30 pm

DEBATE: Bisphosphonates or monoclonal antibodies?

Bisphosphonates
James R. Berenson, MD

Monoclonal Antibodies
Noopur Raje, MD

6:10 pm

Adjourn


Friday, October 27, 2017

8:00 am

Welcome
Morton Coleman, MD

CHRONIC LYMPHOCYTIC LEUKEMIA SESSION

8:05 am

Introduction to CLL Session
Richard R. Furman, MD

Session VIII: Application of Novel Testing to the Clinic

Moderator: Richard R. Furman, MD

8:10 am

Pre-session audience survey

8:20 am

Introduction to Gebroe Family Lecture
Presenter: Morton Coleman, MD

8:30 am

Gebroe Family Lecture: Drug-Drug interactions in the era of TKIs
Alexey V. Danilov, MD, PhD

8:50 am

Minimal residual disease (MRD): Is it clinically relevant?
Peter Hillmen, MB, ChB, PhD

9:10 am

Risk Assessment in the Era of Novel Agents: What prognostic factors are clinically relevant?
Richard R. Furman, MD

9:30 am

Panel discussion and post-session audience survey

9:45 am

Break

Session IX: Novel Small Molecules

Moderator: Kanti Rai, MD

10:05 am

Pre-session audience survey

10:10 am

Long-term updates on ibrutinib and idelalisib
Neil E. Kay, MD

10:30 am

Ibrutinib: real world experience
Anthony R. Mato, MD

10:50 am

Ibrutinib resistance: Is it predictable? What to do?
Richard R. Furman, MD

11:10 am

Role of PI3K inhibitors in clinical practice: Uses and pitfalls
Jennifer R. Brown, MD, PhD

11:30 am

Other new molecules in the pipeline: PI3K inhibitors, SYK inhibitors, etc.
Ian Flinn, MD

11:50 am

Panel discussion and post-session audience survey

12:05 pm

Lunch commercial programs

Session X: Special Topics in CLL I

Moderator: John N. Allan, MD

1:35 pm

Pre-session audience survey

1:45 pm

Update on Venetoclax
Steven Coutre, MD

2:05 pm

Richter’s syndrome: What are the options?
John N. Allen, MD

2:25 pm

Introduction to the Prince Family Lecture
Presenter: Morton Coleman, MD

2:35 pm

Prince Family Lecture: Clonal Evolution in CLL
Dan A. Landau, MD, PhD

2:55 pm

Panel Discussion and post session audience survey

3:10 pm

Break

Session XI: Special Lectures in CLL

Moderator: Nicholas Chiorazzi, MD

3:30 pm

Update from the IWCLL 2017
Michael Hallek, MD

3:50 pm

Introduction to the Bruce Waterfall Memorial Debate in Waldenstrom macroglobulinemia (WM)
Presenter: Morton Coleman, MD

4:00 pm

DEBATE: What is the treatment choice for Waldenstrom macroglobulinemia?

Bendamustine
Stephen M. Ansell, MD, PhD

Ibrutinib
Steven Treon, MD, PhD, FRCP

4:30 pm

Panel discussion and questions

4:45 pm

Adjourn


Saturday, October 28, 2017

8:00 am

Welcome
Morton Coleman, MD

LYMPHOMA SESSION

8:05 am

Introduction to Lymphoma Session
John P. Leonard, MD

Session XII: Emerging Science

Moderator: Leandro Cerchietti, MD

8:10 am

Pre-session audience survey

8:20 am

What can canine lymphomas teach us about the treatment of human lymphomas?
Kristy L. Richards, MD, PhD

8:40 am

Will circulating tumor DNA have clinical utility in management of diffuse large B-cell lymphoma and follicular lymphoma??
Ash A. Alizadeh, MD, PhD

9:00 am

What new targets may have clinical relevance soon in diffuse large B-cell lymphoma?
Ari M. Melnick, MD

9:20 am

Panel discussion and post-session audience survey

9:35 am

Break

Session XIII: Treatment

Moderator: Peter Martin, MD

9:55 am

Pre-debate survey

10:05 am

DEBATE: How should an early progressor after bendamustine based treatment with follicular lymphoma be treated?

Autologous stem cell transplant
Carla Casulo, MD

Novel agents
Brian K. Link, MD

10:35 am

Post-debate audience survey and Pre-debate survey

10:45 am

DEBATE: What is the best treatment approach for relapsed mantle cell lymphoma?

Allogeneic stem cell transplant
Koen van Beisen, MD, PhD

Novel agents
Peter Martin, MD

11:15 am

Post-debate survey

11:20 am

Key data from the International Conference on Malignant Lymphoma in Lugano, Switzerland
Michele Ghielmini, MD

Session XIV: Awards

Moderator: Morton Coleman, MD

11:45 am

Presentation of best lymphoma abstract

11:55 am

The SAAS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD, FACP, President & Director of Research for the SASS Foundation

Presentation: John Ultmann Award for contributions to lymphoma research
Presenter: David G. Maloney, MD, PhD
Recipient: Oliver W. Press, MD, PhD

12:10 pm

CAR-T Therapy in Lymphoma and CLL
David G. Maloney, MD, PhD

12:30 pm

Discussion and post survey

12:45 pm

Luncheon

2:15 pm

Exhibit viewing

Session XV-A: Aggressive B- and T Cell Lymphoma

Parallel with Session XV-B: Indolent and Hodgkin lymphomas
Moderator: Sarah C. Rutherford, MD

2:30 pm

Pre-session audience survey

2:40 pm

What is the best initial therapy for peripheral T cell lymphoma?
Jia Ruan, MD, PhD

3:00 pm

Key novel agents for recurrent T cell lymphoma
Barbara Pro, MD

3:20 pm

What diffuse large B-cell lymphoma patients should receive therapy different from R-CHOP?
John P. Leonard, MD

3:40 pm

Maintenance Therapy: Is it of value in Advanced diffuse large B-cell lymphoma?
Andre P. Goy, MD

4:00 pm

Key novel agents for relapsed diffuse large B-cell lymphoma
Sven de Vos, MD, PhD

4:20 pm

Panel discussion and post-session audience survey

4:35 pm

What is the best therapy for primary mediastinal diffuse large B-cell lymphoma
Anne S. LaCasce, MD, MMSc

4:55 pm

Adjourn

Session XV-B: Indolent and Hodgkin Lymphomas

Parallel with Session XV-A: Aggressive B- and T cell Lymphoma
Moderator: Morton Coleman, MD

2:30 pm

Pre-session audience survey

2:40 pm

Do any prognostic tools offer value in managing patients with Hodgkin lymphoma?
Catherine S.M. Diefenbach, MD

3:00 pm

What is the future of checkpoint-inhibitor therapy in Hodgkin lymphoma?
Robert W. Chen, MD

3:20 pm

How should we manage lymphocyte predominant Hodgkin lymphoma?
Andrew Evens, DO, MSc

3:40 pm

Pre-debate audience survey

3:50 pm

DEBATE: What is the best initial therapy for initial treatment of high tumor burden follicular lymphoma?

CHOP-based based therapy (and should it be with obinutuzumab or rituximab?)
Andrew D. Zelenetz, MD

Bendamustine-based therapy (and should it be with obinutuzumab or rituximab?)
Jonathan Friedberg, MD

4:20 pm

Marginal Zone Lymphoma
Morton Coleman, MD

4:40 pm

Panel discussion and post-session audience survey

4:55 pm

Adjourn

 

NURSING & ADVANCED PRACTITIONERS TRACK

Saturday, October 28, 2017

Session I: Updates in Hematology

Session Chair: Jeremy T. Heinerich, PA-C

8:10 am

Welcome and introduction of Track Moderator
Morton Coleman, MD

8:15 am

Track Overview
Jeremy T. Heinerich, PA-C

8:20 am

Pre-session Audience Survey

8:30 am

Managing CLL
Emilee Thomas, MPH, PA-C

9:15 am

Cytogenetics and molecular markers in myeloma, lymphoma, and CLL
Maureen Thyne, RPA-C, CG(ASCP)

10:00 am

Break

10:20 am

Updates in lymphoma
Nadia Kralovic, PA-C

11:05 am

Updates in myeloma
Arthur Perry, PA-C

11:50 am

New agents within the last 2 years for myeloma, lymphoma, and CLL
Jennifer Santamala, RPh

12:35 pm

Post-session Audience Survey

12:45 pm

Lunch

2:15 pm

Exhibit viewing

Session II: Hematology Workshop

Session Chair: Jeremy T. Heinerich, PA-C

2:30 pm

Pre-session Audience Survey

2:35 pm

Practical tips for bone marrow biopsies and lumbar punctures
Jeremy T. Heinerich, PA-C, Emile Thomas, PA-C, and Maureen Thyne, RPA-C, CG(ASCP)

3:15 pm

Practical hands on experience for bone marrow biopsies and lumbar punctures
Jeremy T. Heinerich, PA-C, Emile Thomas, PA-C, and Maureen Thyne, RPA-C, CG(ASCP)

4:45 pm

Post-session Audience Survey

4:55 pm

Adjourn